{"id":"W2946878839","doi":"10.1200/jco.2019.37.15_suppl.5520","title":"Mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients (pts) with platinum-resistant ovarian cancer: Final findings from the FORWARD II study.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Bevacizumab; Internal medicine; Adverse effect; Gastroenterology; Nausea; Ovarian cancer; Combination therapy; Cancer; Oncology; Surgery; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001320468,0.0006980105,0.001188068,0.0003175003,0.0001947236,0.0007226301,0.0005430308,0.0007174453,0.00165528],"category_scores_gemma":[0.0009097491,0.0004481515,0.0009943547,0.0004442732,0.000339399,0.0005333038,0.0002885385,0.001214319,0.0003982237],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001046575,"about_ca_system_score_gemma":0.0007992598,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001195276,"about_ca_topic_score_gemma":0.003685189,"domain_scores_codex":[0.9995556,0.0002249823,0.00004140939,0.00005777969,0.00005619996,0.00006392184],"domain_scores_gemma":[0.999509,0.00009763496,0.0001376388,0.00003004804,0.00003293742,0.0001928755],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.5261792,0.03772445,0.04643416,0.002162104,0.004146737,0.001119137,0.0007882775,0.004737654,0.07384729,0.0002447706,0.004631576,0.2979846],"study_design_scores_gemma":[0.2181193,0.6771654,0.08387411,0.0001158973,0.00226765,0.001518617,0.0001481232,0.001856843,0.00712615,0.0001206489,0.007642097,0.00004510859],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9926434,0.005089228,0.0002566254,0.0002481228,0.00003717807,0.0004572769,0.0004199792,0.00002691226,0.0008211803],"genre_scores_gemma":[0.9926994,0.003434265,0.0008403716,0.0003789565,0.00008280576,0.0002920408,0.001316181,0.00001271862,0.0009432135],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00165528,"threshold_uncertainty_score":0.007593393,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03562944057236112,"score_gpt":0.3737685522482352,"score_spread":0.3381391116758741,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}